Hend A. Nooh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hend A. Nooh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Bayoumi
Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
2 shared publications - Rasha M. Abdel Hamid
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo 11562, Egypt
2 shared publications Eman Z. Kandeel
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publicationFarida M. Mahmoud
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11562, Egypt
1 shared publication- Lobna Abdel Azeem Refaat
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11562, Egypt
1 shared publication Lobna Refaat
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication
Latest Publications
- 25 June 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1)
Bone marrow hemophagocytosis in patients with hematological malignancies and COVID-19 infections: mimicry or secondary HLH?
Severe coronavirus disease 2019 (COVID-19) and secondary hemophagocytic lymphohistiocytosis (sHLH) share overlapping pathogenesis, symptoms, and ultimately fatal outcomes unless prompt early interventions are undertaken. The excessive immune response in COVID-19 may increase hemophagocytes in bone marrow aspirate (BMA), which could mimic sHLH. We aimed to assess hemophagocytic cells in the BM of COVID-19 patients with hematological neoplasms and examine their link to sHLH. BMAs from 44 living COVID-19-positive patients with hematological neoplasms were examined, focusing on the presence of hemophagocytic cells. Alongside clinical and laboratory data, patients were classified into two groups according to the HLH-2004 diagnostic criteria: those meeting ≥ 4 criteria (n = 23) and those meeting < 4 criteria (n = 21). BMAs from 44 COVID-19-negative patients with similar hematological malignancies were also analyzed for comparison. Hemophagocytic cells were present in 33/44 (75.0%) COVID-19-positive patients and were associated with normal and increased erythropoiesis (p = 0.044). Hemophagocytosis was significantly more frequent in COVID-19-positive than in COVID-19-negative patients (p < 0.001). Meeting ≥ 4 HLH-2004 criteria was significantly more prevalent in newly diagnosed patients than in those during follow-up/relapse (p = 0.004). Significantly higher H-scores were also observed in newly diagnosed patients compared with those in follow-up (p < 0.001). Patients with severe/critical COVID-19 or intensive care unit (ICU) admission had higher H-scores; however, the differences were not statistically significant (p = 0.509 and 0.246, respectively). Hemophagocytic cells are significantly observed in COVID-19 patients with hematological neoplasms, but are insufficient to support a classic diagnosis of concurrent sHLH. These findings suggest that COVID-19-associated hyperinflammation may contribute to BM hemophagocytosis in this vulnerable population.
- 25 June 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1)
Bone marrow hemophagocytosis in patients with hematological malignancies and COVID-19 infections: mimicry or secondary HLH?
Severe coronavirus disease 2019 (COVID-19) and secondary hemophagocytic lymphohistiocytosis (sHLH) share overlapping pathogenesis, symptoms, and ultimately fatal outcomes unless prompt early interventions are undertaken. The excessive immune response in COVID-19 may increase hemophagocytes in bone marrow aspirate (BMA), which could mimic sHLH. We aimed to assess hemophagocytic cells in the BM of COVID-19 patients with hematological neoplasms and examine their link to sHLH. BMAs from 44 living COVID-19-positive patients with hematological neoplasms were examined, focusing on the presence of hemophagocytic cells. Alongside clinical and laboratory data, patients were classified into two groups according to the HLH-2004 diagnostic criteria: those meeting ≥ 4 criteria (n = 23) and those meeting < 4 criteria (n = 21). BMAs from 44 COVID-19-negative patients with similar hematological malignancies were also analyzed for comparison. Hemophagocytic cells were present in 33/44 (75.0%) COVID-19-positive patients and were associated with normal and increased erythropoiesis (p = 0.044). Hemophagocytosis was significantly more frequent in COVID-19-positive than in COVID-19-negative patients (p < 0.001). Meeting ≥ 4 HLH-2004 criteria was significantly more prevalent in newly diagnosed patients than in those during follow-up/relapse (p = 0.004). Significantly higher H-scores were also observed in newly diagnosed patients compared with those in follow-up (p < 0.001). Patients with severe/critical COVID-19 or intensive care unit (ICU) admission had higher H-scores; however, the differences were not statistically significant (p = 0.509 and 0.246, respectively). Hemophagocytic cells are significantly observed in COVID-19 patients with hematological neoplasms, but are insufficient to support a classic diagnosis of concurrent sHLH. These findings suggest that COVID-19-associated hyperinflammation may contribute to BM hemophagocytosis in this vulnerable population.
- 30 May 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (7) , 102741
Unraveling mortality risks in pediatric oncology: Exploring bloodstream coinfections and inflammatory biomarkers in COVID-19
- 30 May 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (7) , 102741
Unraveling mortality risks in pediatric oncology: Exploring bloodstream coinfections and inflammatory biomarkers in COVID-19
- Open Access
- 27 March 2023
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 24 (1) , 1-11
The expression level of ARF and p53 in AML patients, and their relation to patients' outcome
Background: Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory genes, e.g., alternate open reading frame (ARF), whose defects could affect p53 activity. Aim: To study the effect of altered expression of p53 and ARF genes in de novo AML patients and correlate the results to the patients’ characteristics and outcomes. Methods: Expression levels of p53 and ARF were assessed in 96 AML adult patients compared to 20 healthy controls using quantitative reverse-transcription PCR (RT-qPCR). Results: There was significant up-regulation of p53 [77.6 (3.8–9528.3)] compared to controls [1.031 (0.210–9.051)], p < 0.001]. The expression level of ARF was significantly upregulated [6.2 (0.5–964.0)] compared to controls [0.854 (0.357–2.519), p < 0.001]. All of the low ARF expressers had low p53 overexpression, 61.1% of patients with high ARF expression had high p53 over-expression, and 38.9% with high ARF expression had low p53 over-expression (p < 0.001). ARF expression shows a trend of association with FLT3 mutation, as 89.3% with FLT3 mutation have high ARF expression (p = 0.080). Low p53 over-expression was seen in 77% of APL patients, while high p53 expression was associated with non-APL (p = 0.040). The median DFS of mutant NPM1 patients was higher than wild NPM1 (46.15 vs. 5.89 days, p = 0.045). Patients aged ≤ 50 years had better OS and DFS than those > 50 (p = 0.05, p = 0.035, respectively).There were no significant statistical associations between DFS and p53, ARF, and FLT3 mutations. Conclusion: The p53 and ARF genes are overexpressed in de novo AML patients and they are interrelated. low p53 overexpression is associated with APL phenotype and t(15;17) and patients with t(15;17) had slightly better survival than patients with negative t(15;17) (p = 0.061). AML patients with mutated NPM1 had better DFS than wild NPM1 (p = 0.045). p53 pathway regulation can occur by many alternative ways rather than gene mutation.
- 27 March 2023
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 24 (1) , 1-11
Open AccessThe expression level of ARF and p53 in AML patients, and their relation to patients' outcome
Background: Acute myeloid leukemia (AML) is a cancer of hematopoietic progenitors characterized by gene mutations. The most popular deregulations are mutation and altered expression in the p53 gene, which is considered the guardian of the genome. Its activity is controlled by regulatory genes, e.g., alternate open reading frame (ARF), whose defects could affect p53 activity. Aim: To study the effect of altered expression of p53 and ARF genes in de novo AML patients and correlate the results to the patients’ characteristics and outcomes. Methods: Expression levels of p53 and ARF were assessed in 96 AML adult patients compared to 20 healthy controls using quantitative reverse-transcription PCR (RT-qPCR). Results: There was significant up-regulation of p53 [77.6 (3.8–9528.3)] compared to controls [1.031 (0.210–9.051)], p < 0.001]. The expression level of ARF was significantly upregulated [6.2 (0.5–964.0)] compared to controls [0.854 (0.357–2.519), p < 0.001]. All of the low ARF expressers had low p53 overexpression, 61.1% of patients with high ARF expression had high p53 over-expression, and 38.9% with high ARF expression had low p53 over-expression (p < 0.001). ARF expression shows a trend of association with FLT3 mutation, as 89.3% with FLT3 mutation have high ARF expression (p = 0.080). Low p53 over-expression was seen in 77% of APL patients, while high p53 expression was associated with non-APL (p = 0.040). The median DFS of mutant NPM1 patients was higher than wild NPM1 (46.15 vs. 5.89 days, p = 0.045). Patients aged ≤ 50 years had better OS and DFS than those > 50 (p = 0.05, p = 0.035, respectively).There were no significant statistical associations between DFS and p53, ARF, and FLT3 mutations. Conclusion: The p53 and ARF genes are overexpressed in de novo AML patients and they are interrelated. low p53 overexpression is associated with APL phenotype and t(15;17) and patients with t(15;17) had slightly better survival than patients with negative t(15;17) (p = 0.061). AML patients with mutated NPM1 had better DFS than wild NPM1 (p = 0.045). p53 pathway regulation can occur by many alternative ways rather than gene mutation.